


## Claims

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, where:

**Q** is a cyclobutyl or cyclopentyl ring, each of which is optionally substituted by one hydroxy or methoxy group, or **Q** is an oxetanyl, tetrahydrofuranyl or oxanyl ring, each of which is optionally substituted by one methyl group;

**R**<sup>1</sup> is methyl;

**R**<sup>2</sup> is hydrogen or methyl; or **R**<sup>1</sup> and **R**<sup>2</sup> together form an azetidiny, pyrrolidinyl or piperidinyl ring;

**R**<sup>3</sup> is hydrogen or fluoro;

**R**<sup>4</sup> is hydrogen or methyl; and

**R**<sup>5</sup> is hydrogen or fluoro.

2. The compound of Formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, where **Q** is cyclobutyl, 1-methoxy-cyclobut-3-yl, 1-hydroxy-cyclobut-3-yl, 3-methoxycyclopent-1-yl, oxetan-3-yl, tetrahydrofuran-3-yl, oxan-3-yl, oxan-4-yl or 4-methyloxan-4-yl.

3. The compound of Formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, where **Q** is 1-methoxy-cyclobut-3-yl, 1-hydroxy-cyclobut-3-yl or oxan-4-yl.

4. The compound of Formula (I) as claimed in claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, where **R**<sup>1</sup> is methyl and **R**<sup>2</sup> is hydrogen or methyl.

5. The compound of Formula (I) as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, where **R<sup>3</sup>** and **R<sup>5</sup>** are both hydrogen.

6. The compound of Formula (I) as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, where **R<sup>4</sup>** is methyl.

7. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 where:

**Q** is 1-methoxy-cyclobut-3-yl, 1-hydroxy-cyclobut-3-yl, 3-methoxycyclopent-1-yl, oxetan-3-yl, oxan-3-yl, oxan-4-yl or 4-methyloxan-4-yl;

**R<sup>1</sup>** is methyl;

**R<sup>2</sup>** is hydrogen or methyl; or **R<sup>1</sup>** and **R<sup>2</sup>** together form an azetidiny, pyrrolidinyl or piperidinyl ring;

**R<sup>3</sup>** is hydrogen or fluoro;

**R<sup>4</sup>** is hydrogen or methyl; and

**R<sup>5</sup>** is hydrogen or fluoro.

8. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-(*cis*-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-3-methyl-1-(4-methyloxan-4-yl)imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxetan-3-yl)imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-(*cis*-3-hydroxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-1-(*cis*-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(4-methyloxan-4-yl)imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-3-methyl-1-(oxetan-3-yl)imidazo[5,4-c]quinolin-2-one;

5 8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-3-methyl-1-[(3*R*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-7-fluoro-3-methyl-1-[(3*S*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

10 8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-(*cis*-3-methoxycyclobutyl)-3H-imidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-(oxan-4-yl)-3H-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(Azetidin-1-yl)propoxy]pyridin-3-yl]-1-(*cis*-3-hydroxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

15 1-(3-*cis*-Hydroxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-[(3*R*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

20 8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-[(3*S*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)-2-fluoropyridin-3-yl]-1-(*cis*-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)-2-fluoropyridin-3-yl]-7-fluoro-1-(*cis*-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-one;

25 8-[6-(3-Dimethylaminopropoxy)-2-fluoropyridin-3-yl]-3-methyl-1-[(3*S*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)-2-fluoropyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one;

30 8-[6-(3-Dimethylaminopropoxy)-2-fluoropyridin-3-yl]-3-methyl-1-[(3*R*)-oxan-3-yl]imidazo[5,4-c]quinolin-2-one;

7-Fluoro-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-one;

7-Fluoro-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-[(1*R*,3*R*)-3-methoxycyclopentyl]-3-methylimidazo[4,5-*c*]quinolin-2-one;

8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-1-[(1*S*,3*S*)-3-methoxycyclopentyl]-3-methylimidazo[4,5-*c*]quinolin-2-one;

5 7-Fluoro-1-(*cis*-3-methoxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-*c*]quinolin-2-one;

1-(*cis*-3-Methoxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-*c*]quinolin-2-one;

10 3-Methyl-1-[(3*S*)-oxan-3-yl]-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[5,4-*c*]quinolin-2-one;

3-Methyl-1-(oxan-4-yl)-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]imidazo[5,4-*c*]quinolin-2-one;

3-Methyl-1-[(3*S*)-oxan-3-yl]-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]imidazo[5,4-*c*]quinolin-2-one;

15 3-Methyl-1-[(3*R*)-oxan-3-yl]-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]imidazo[5,4-*c*]quinolin-2-one;

1-(*cis*-3-Methoxycyclobutyl)-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]imidazo[4,5-*c*]quinolin-2-one;

20 8-[6-[3-(Azetidin-1-yl)propoxy]pyridin-3-yl]-3-methyl-1-[(3*R*)-oxan-3-yl]imidazo[5,4-*c*]quinolin-2-one;

1-(*cis*-3-Methoxycyclobutyl)-8-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]-3*H*-imidazo[4,5-*c*]quinolin-2-one;

1-(Oxan-4-yl)-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-3*H*-imidazo[4,5-*c*]quinolin-2-one;

25 3-Methyl-1-(oxan-4-yl)-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]imidazo[5,4-*c*]quinolin-2-one;

8-[6-[3-(Azetidin-1-yl)propoxy]pyridin-3-yl]-1-(*cis*-3-methoxycyclobutyl)-3-methylimidazo[4,5-*c*]quinolin-2-one;

30 8-[6-[3-(Azetidin-1-yl)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-*c*]quinolin-2-one;

3-Methyl-8-[6-(3-methylaminopropoxy)pyridin-3-yl]-1-(oxan-4-yl)imidazo[5,4-*c*]quinolin-2-one;

3-Methyl-8-[6-(3-methylaminopropoxy)pyridin-3-yl]-1-[(3*S*)-oxan-3-yl]imidazo[5,4-*c*]quinolin-2-one; and

1-(*cis*-3-Methoxycyclobutyl)-3-methyl-8-[6-(3-methylaminopropoxy)pyridin-3-yl]imidazo[4,5-*c*]quinolin-2-one;

3-Methyl-8-[6-[3-(methylamino)propoxy]-3-pyridyl]-1-[(3*R*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

5 8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-3-methyl-1-[(3*R*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-3-methyl-1-[(3*S*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

10 1-Cyclobutyl-8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

7-Fluoro-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-7-fluoro-3-methyl-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

15 8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-3-methyl-1-[(3*S*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-3-methyl-1-[(3*R*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

20 1-Cyclobutyl-8-[6-[3-(dimethylamino)propoxy]-2-fluoro-3-pyridyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-3-methyl-1-(oxetan-3-yl)imidazo[4,5-*c*]quinolin-2-one;

7-Fluoro-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-tetrahydropyran-4-yl-imidazo[4,5-*c*]quinolin-2-one

25 3-Methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-[(3*R*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

3-Methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-[(3*S*)-tetrahydrofuran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

30 3-Methyl-1-(oxetan-3-yl)-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

1-Cyclobutyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

1-Cyclobutyl-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

3-Methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-[(3*R*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Azetidin-1-yl)propoxy]-3-pyridyl]-3-methyl-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

5 8-[2-Fluoro-6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-3-methyl-1-[(3*S*)-tetrahydropyran-3-yl]imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-[(1*R*,3*R*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

10 8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-[(1*S*,3*S*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

1-[(1*R*,3*R*)-3-Methoxycyclopentyl]-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

1-[(1*S*,3*S*)-3-Methoxycyclopentyl]-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

15 1-[(1*S*,3*S*)-3-Methoxycyclopentyl]-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

1-[(1*R*,3*R*)-3-Methoxycyclopentyl]-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-*c*]quinolin-2-one;

20 8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-1-[(1*R*,3*R*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-2-fluoro-3-pyridyl]-1-[(1*S*,3*S*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-[(1*R*,3*S*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one; and

25 8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-[(1*S*,3*R*)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-*c*]quinolin-2-one.

9. The compound of Formula (I), which is 8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-*c*]quinolin-2-one or a pharmaceutically acceptable salt thereof.

10. The compound of Formula (I), which is 8-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-*c*]quinolin-2-one.

11. The compound of Formula **(I)**, which is a pharmaceutically acceptable salt of 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one.
12. A crystalline form (Form A) of 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one, which has an X-ray powder diffraction pattern (obtained using copper radiation) with at least two specific peaks at 2-theta = 3.9 and 11.6° (plus or minus 0.2° 2-theta).
13. A pharmaceutical composition which comprises a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12, and at least one pharmaceutically acceptable diluent or carrier.
14. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12, for use in therapy.
15. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use as claimed in claim 14, wherein said therapy is the treatment of cancer.
16. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, as claimed in claim 15, where the compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof is administered in combination with radiotherapy.
17. A compound of Formula **(I)** or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, as claimed in claim 15, where the compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736, AZD1775 and AZD6738.

18. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, as claimed in any one of claims 15 to 17, wherein said cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, triple negative breast cancer, hepatocellular carcinoma, small cell lung cancer and non-small cell lung cancer.
- 5